Triazoles antifungals can display unpredictable pharmacokinetics in critically-ill or severely immunocompromised patients making it difficult to predict whether patients will achieve safe and effective drug exposures. In light of the high morbidity and mortality associated with invasive fungal diseases, many treatment guidelines have advocated therapeutic drug monitoring (TDM) for patients receiving mould-active triazole therapy, even though the introduction of newer posaconazole formulations and isavuconazole has renewed debate whether routine TDM is necessary. In this session, we will discuss the current evidence and controversies surrounding TDM for triazole antifungals, address strategies for rationale-selective TDM in high risk patients populations, and discuss major unmet challenges and future role of TDM for advancing individualised antifungal therapy at the bedside.
Full conference title:
- TIMM 8th (2017)